Purpose: The aim of this paper is to present a simple and quantitative data analysis method with a new potential in the application of liver single-photon emission computed tomography (SPECT) imaging. We have established quantitative SPECT/computed tomography (CT) in vivo imaging protocols for determination of liver tumor burden based on the known role of Kupffer cells in cancer of the liver. Procedures: As it is also known that functional Kupffer cells accumulate particulate material contained in the arterial blood of liver supply, we used radiolabeled macro-aggregated albumin particles ([ 99m Tc]-MAA) injected intravenously to image liver disease. Quantification of cold spot liver lesion imaging was also a general objective. Methods: We examined a healthy control group (BALB/C mice, n=6) and group of induced hepatocellular carcinoma (HCC, matrilin-2 transgenic KO mice, n=9), where hepatocellular carcinoma was induced by diethylnitrosamine. We used [ 99m Tc]-MAA as radiopharmaceutical for liver SPECT imaging in a small animal SPECT/CT system. A liver radioactivity overview map was generated. Segmentation of the liver was calculated by Otsu thresholding method. Based on the segmentation the radioactivity volume and the summarized liver activity were determined. Results: Tumor burden of the livers was quantitatively determined by creating parametric data from the resulting volumetric maps. Ex vivo liver mass data were applied for the validation of in vivo measurements. An uptake with cold spots as tumors was observed in all diseased animals in SPECT/ CT scans. Isotope-labeled particle uptake (standardized uptake concentration) of control (median 0.33) and HCC (median 0.18) groups was significantly different (p=0.0015, Mann Whitney U test).
Introduction
H epatocellular carcinoma (HCC) is the third leading cause of cancer mortality worldwide and it is the most common primary cancer of the liver [1] . Furthermore, liver
Electronic supplementary material The online version of this article (doi:10.1007/s11307-013-0679-y) contains supplementary material, which is available to authorized users. imaging is commonly undertaken in patients with history of cancer because the liver is one of the most frequently involved organs by metastatic disease either as source or target [2] . Several imaging modalities are now available for detection and characterization of tumorous lesions in the liver: ultrasonography, computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET), and singlephoton emission computed tomography (SPECT). The availability of combined functional/anatomical imaging modalities that integrate the benefits of visualizing tumor biology with those of high-resolution structural imaging revolutionized both clinical and preclinical imaging. The latter can be very important to translate new, more specific, and sensitive methods of liver cancer diagnostics as well as therapeutic potential to the clinic.
In clinical practice, the most commonly used liver tumor detection methods are based on anatomical imaging techniques such as X-ray CT methods and different MRI-based solutions-diffusion weighted imaging (DWI) and contrast enhanced T 1 -weighted imaging and small paramagnetic iron oxide particle (SPIO) imaging. DWI tumor detection is based on the phenomenon of decreased water molecule diffusion coefficients due to increased cellularity levels in the lesion [3] . Contrast-enhanced CT which is widely available and familiar with the general radiologist is the mainstay of hepatic imaging [4] . The accuracy of CT is poor at a smaller (G2 mm) tumor size and an MRI should be performed to fully evaluate the liver but in these cases, the false-positive rate increases [5] .
Imaging radiolabeled compounds with SPECT and PET is often carried out to provide insight into a tumor's biological functions. Despite their high sensitivity and specificity, tomographic SPECT and PET are substantially limited by low spatial resolution and inability to provide anatomical detail [6] . Some HCC-specific radiopharmaceuticals as [ 11 C]-acetate, [ 11 C]-choline, and 2-deoxy-2-[ 18 F] fluoro-D-glucose are used in PET imaging [7] [8] [9] . Quantification of the metabolic rate of tumor cells and its visualization in parametric images can provide an enhanced sensitivity of diagnosis in dubious cases [10, 11] . More advantageous are those SPECT and PET imaging methods that provide hot-spot imaging where radiopharmaceuticals or radiopeptides are uptaken by tumors in a larger extent than healthy liver tissue. On the other hand, a widely available radiotracer for uniformly positive HCC cell uptake in all or even the majority of patients still can be considered missing, as [ 11 C]-labeled compounds require special radiochemistry and a nearby cyclotron, whereas [ 18 F]-choline is not showing positive contrast in tumors of all patients [12] .
In the past and in current clinical practice, liver radioscintigraphy and SPECT imaging with macro-aggregated albumin ( [17] . The method of SPIO MR imaging is also based on Kupffer cell particle uptake and it shows the same diagnostic sensitivity as other MRI techniques [18] .
In previous unpublished experiments in the same tumor model, our attempts to obtain positive focal tumor contrast with several radiotracers for SPECT have not provided satisfactory results. These experiments are also briefly referred in the "Material and Methods" and "Results" sections. Based on these literature data and experience, we supposed that screening of Kupffer cells using MAA in SPECT imaging helps to sensitively detect tumorous lesions in the liver as cold spots. According to previously published in vitro and clinical studies based on the correlation between HCC and mean number of liver Kupffer cells, quantitative SPECT/CT in vivo imaging methods and image analysis could estimate tumor grade and stage of liver lesions too [16] . The aim of this article is to present a preclinical study and a simple data analysis method that could show a new potential application of MAA for clinical practice too. Therefore, the often difficult interpretation of cold-spot images is made easier using the analysis described herein. Our intention was to find an appropriate, simple, and straightforward in vivo surrogate of tumor burden determination. It was of paramount importance that this method should be easily executed on in vivo in situ liver data.
Material and Methods
We examined a healthy control group (BALB/c, C3H, C57BL/6 mice, n=2-2-2, m=34.2±11 g) and a HCC group (cancer-prone matrilin-2 transgenic KO mice (MATN2) with chemically induced hepatocellular carcinoma, n=9, m=38.5±2 g). Hepatocellular carcinoma was induced by diethylnitrosamine on 15-days-old male mice via i.p. injection. The imaging was performed 4 months after induction. The presence of tumorous lesions was proved by histology in Haematoxylin-Eosin-stained 10-μm-thin sections (Electronic supplementary material (ESM) 1). All our experiments were conducted according to applicable national and European Union legislation and previously obtained the ethical approval of the Municipal and the Local Animal Care and Use Committee (permission no. XIV-I-001/ 29-7/2012).
In preparation, our group has experimented with different other radiotracers to enable selective and positive contrast imaging of HCC models in mice. In previous proof-of-concept experiments in groups of n=4 HCC-induced mice of the same model we applied Animals were anesthetized by the injection of 800 mg/kg body weight dose of 10 % solution of urethane injection intraperitoneally (i.p.). We used [
99m Tc]-MAA (Nano-Albumon, Medi-radiopharma Ltd, Budapest, Hungary, mean diameter G 200 nm, with 2-5 GBq/mg specific activity), as radiopharmaceutical for Kupffer cell imaging (0.1-0.22 ml, 90 MBq/ animal (A total ) i.v., 2 h post-injection) for helical liver SPECT imaging (17-18-min scan time) with a voxel size of 200 μm, and eXIA160 (Binitio Biomedical, Inc., Ottawa, CA) small animal contrast material (0.1 ml/20 g iv, 2 h post-injection imaging) for liver CT imaging to enhance liver contrast (9-min scan time) with voxel size of 36 μm (NanoSPECT/CT Plus Silver Upgrade, Mediso Ltd., Hungary). For the segmentation of the liver, images were processed first by visually delineating a volume of interest containing only the liver and the body as background (this process was assisted by the CT image). Thereafter, Otsu thresholding method was run on this segmented SPECT image volume in VivoQuant (inviCRO, Boston, USA) image analysis software to obtain a reliable and automatic delineation of liver versus non-liver volumes [19] . Based on the segmentation the radioactivity volume (V liver ) and the summarized liver activity (A liver ) were determined. Several semi quantitative techniques may be used to express the accumulation of radiotracers in tumors and normal tissues, including standardized uptake value (SUV). This has been described as a method of expressing biologic tissue distribution or relative concentration of radiotracers following i.v. administration in a variety of species [20, 21] .
In our process, a measurend called standardized uptake concentration (SUC, Eq. 1.) per animal were obtained from quantified SPECT data [22] .
SUC ¼
A liver A total V liver ð1Þ
After the last imaging session, the animals were culled by i.p. injection of 0.5 ml of euthanasia agent (T61®, Bayer, Germany) and an autopsy was performed. The livers were carefully removed by hand, placed in a filter paper sheet and then mass of each animal's liver was measured using an ABJ220-4M Precision Balance (Kern & Sohn GmbH, Balingen, Germany) with 0.1 g precision. Ex vivo liver tumor mass was used as objective parameter and was applied for the validation of in vivo measurements to correlate tumor burden measured by SPECT and in vivo really present tumor mass in the liver.
Statistical Calculations
To compare control and HCC groups, Mann Whitney U test was applied. To check the relationship between ex vivo liver mass and segmented liver volume (i.e., to account for validity of SPECT measurement segmentation), Spearman's correlation test was used. 
Results
Positive tumor focus contrast SPECT imaging was not achievable in our experience by the applied radiotracers Fig. 1 . images show the CT reconstruction of the whole body with a window to present the skeleton (left), the 99m Tc isotope-labeled MAA uptake in liver segmented by Otsu method 2 h after the injection (center) and the 3D VOI created on the basis of the SPECT images. Based on this process the livers of all the animals were segmented.
In our experiment [ 99m Tc]-MAA was detectable mainly in the liver and the bladder after two hours. The mean ratio of liver and whole body activity was 42 % (SD, 6 % ) and 51 % (SD, 5 %) in the HCC and control group respectively. Figure 2 presents slices of SPECT and CT reconstructed liver images. Figure 2a shows CT image of healthy control without contrast material and Fig. 2b shows CT image of HCC with contrast material. SPECT image of healthy control (2C) shows homogenous uptake on the other hand HCC (2D) was acquired and the tumorous regions as several cold spots-largest on the left lobe-could be detected. (Other SPECT images of different animals are available as ESM.) For quantification purposes, the SUC (Eq. 1.) was defined being similar to the SUV parameter in PET experiment. We based our SUC measurements on a quantitative, previously calibrated SPECT system. This quantitative parameter helps to estimate the presence of the lesion/cancer, the volume of the lesion and the severity of the cancer.
Based on literature data, we suppose relationship of in vivo defect volumes and tumor volumes [23] . The validation of liver segmentation was examined by establishing the correlation between volume via in vivo segmentation and ex vivo liver mass of HCC group. (Spearman correlation r= 0.93, pG0.001). Liver volume was plotted against liver mass as presented in Fig. 3 .
In Fig. 4 . the box plot shows the SUC of control (median 0.33) and HCC (median 0.18) groups. The difference is statistically significant (p=0.0015, Mann Whitney U test).
Discussion and Conclusions
Based on the results of the SPECT imaging 2 h after the radiopharmaceutical injection we can conclude that the [ 99m Tc]-MAA is accumulated in the liver. In this time frame the MAA was not detectable in the heart and in the blood vessels. Based on literature data we suppose that [
99m Tc]-MAA was taken up by Kupffer cells which are the specialized resident macrophage cells of the liver [17] . The rapid recognition of intravenously injected large size and long blood half-life nanoparticles from the blood by Kupffer cells via a multitude of specialized plasma membrane receptors [24] . The mechanisms of uptake are phagocytosis and macropinocytosis mediated by complement receptors after relatively nonspecific opsonization with complement and by Fc receptors after specific opsonization with antibodies [25] .
We could observe the uptake absence-cold spots-as tumorous lesions in SPECT images in all case of diseased animals. The CT imaging has disadvantages such as longer segmentation and image processing time. Furthermore, the SPECT radiopharmaceutical [
99m Tc]-MAA is much more economical than the available small animal CT contrast agents.
Because of the functional nature of [ 99m Tc]-MAA SPECT, we have information on cellular and even metabolic level uptake of macro-aggregates that is an indirect marker of the intact functioning of the monocyte-macrophage system in the liver. Thus, the information content of these functional images is much more than identifying visible focal lesions-but that information is hidden in the data acquired. The quantitative SUC parameter could present one facet of this additional information. We hereby show the applicability of the SUV concept in quantitative SPECT studies. We found that the distribution of SUC values is very significantly different in the tumorous and control group. Therefore, the SUC value could be a useful tool to differentiate between healthy and tumorous sub-volumes of the liver SPECTs.
This study suggests that SPECT with [ 99m Tc]-MAA can estimate both the presence and the size of tumorous lesions in the liver using a specific data analysis method. The results are promising for later preclinical and clinical practice. Nevertheless, due to the specific model of chemically induced HCC in contrast to the mostly viral origin human HCC morbidities, and in principle, the sample sizes applied in our study would also warrant for thorough examination before the clinical translation.
On the other hand, our method proposed hereby is straightforward and can be applied with minimal changes of the imaging device, the patient protocol and needs only a small data analysis experience. For preclinical use, the method would become a very powerful tool of high-content in vivo hepatotoxicity testing after repeated or even single exposition of new chemical entities.
